539 related articles for article (PubMed ID: 11413522)
1. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
4. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
7. The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
Minerva Ginecol; 2006 Oct; 58(5):393-403. PubMed ID: 17006426
[TBL] [Abstract][Full Text] [Related]
8. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
Soegaard Andersen E; Knudsen A; Svarrer T; Lund B; Nielsen K; Grove A; Tetsche M
Gynecol Oncol; 2005 Dec; 99(3):552-6. PubMed ID: 16150480
[TBL] [Abstract][Full Text] [Related]
9. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
11. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
13. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
14. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic open laparoscopy in the management of advanced ovarian cancer.
Angioli R; Palaia I; Zullo MA; Muzii L; Manci N; Calcagno M; Panici PB
Gynecol Oncol; 2006 Mar; 100(3):455-61. PubMed ID: 16325244
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for advanced ovarian cancer.
Schwartz PE; Chambers JT; Makuch R
Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
[TBL] [Abstract][Full Text] [Related]
17. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease.
Ferron JG; Uzan C; Rey A; Gouy S; Pautier P; Lhommé C; Duvillard P; Morice P
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):101-5. PubMed ID: 19740592
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
19. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
